预约演示
Pneumagen's intranasal flu antiviral stands up to phase 2 human challenge study
2023-10-02
临床2期临床结果临床1期
With the proof of concept in hand, Pneumagen now plans to advance more clinical trials for Neumifil to reduce viral exacerbations in patients with chronic obstructive pulmonary disease.
Pneumagen’s intranasal flu antiviraPneumagenod up to the challenge—a human challenge study,Neumifil. The Scottish company has found that Neumifil rchronic obstructive pulmonary disease and severity of viral respiratory tract infections during a phase 2 proof-of-concept trial.
Pneumagenwas tested in a rare human challenge study, where volunteers are intentionally given an infection and carefully monitored. The mNeumifiltrial featured 104 healthy adults who received two dosesviral respiratory tract infectionse they were exposed to the influenza virus.
Neumifilapy showed a clinically significant reduction in the incidence of symptomatic flu infectiinfection symptom severity, meeting the main goal of the trial. Neumifil was well tolerated, and there were no treatment-emergent adverse events or safety signals ofinfluenzapared to an earlier phase 1 study, the company said.
With the proof of concept in hand, Pneumagen now plans to advance more clisymptomatic flu infection, including to reduce viral exacerbations in patients with chrNeumifiltructive pulmonary disease, or COPD. A phase 2b trial is expected to get underway in 2024.
Neumifil is the lead therapy for StPneumagen, U.K.-based Pneumagen, which spun out of the UNeumifily of St Andrews in Scotland. The company announced 8 milliochronic obstructive pulmonary diseaseinancCOPDin June to support the clinical development program.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。